This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Patient-Physician Relationship/ Care  • Treatment Adherence  • Obesity  • Randomized Controlled Trial  • Drug Therapy  • Adherence  • Alert me on articles by topic  Social Bookmarking   What's this?

Denise G. Simons-Morton, MD, PhD; Eva Obarzanek, PhD, MPH, RD; Jeffrey A. Cutler, MD, MPH

JAMA. 2006;295:826-828.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Obesity is one of the most important public health problems today. An estimated 65% of US adults are overweight or obese,¹ with 112 000 to 280 000 annual deaths attributable to obesity.^2-3 If trends continue, obesity-related deaths may lead to cessation of the increases seen in life expectancy and perhaps to reduced life expectancy in the future,⁴ and obesity will contribute even more adversely to the population's well-being and health care costs in the United States.⁵

Are weight loss medications one solution? In this issue of JAMA, Pi-Sunyer and colleagues⁶ report the results of a clinical trial (RIO-North America) examining the effects of rimonabant on weight and cardiometabolic risk factors. The authors report that a 20 mg/d dose produced a 4.5% weight loss and favorable blood lipid changes compared with placebo after 1 year in a . . . [Full Text of this Article]

Author Affiliations: Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial
F. Xavier Pi-Sunyer, Louis J. Aronne, Hassan M. Heshmati, Jeanne Devin, Julio Rosenstock, and for the RIO-North America Study Group
JAMA. 2006;295(7):761-775.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neighborhood Resources for Physical Activity and Healthy Foods and Incidence of Type 2 Diabetes Mellitus: The Multi-Ethnic Study of Atherosclerosis
Auchincloss et al.
Arch Intern Med 2009;169:1698-1704.
ABSTRACT | FULL TEXT  

Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks et al.
NEJM 2009;360:859-873.
ABSTRACT | FULL TEXT  

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Smith et al.
Diabetes Care 2008;31:1816-1823.
ABSTRACT | FULL TEXT  

Adipose Tissue and Atherosclerosis: Exploring the Connection
Fantuzzi and Mazzone
Arterioscler. Thromb. Vasc. Bio. 2007;27:996-1003.
ABSTRACT | FULL TEXT  

Primary Prevention of Atherosclerotic Cardiovascular Disease: The High Public Burden of Low Individual Risk
Lauer
JAMA 2007;297:1376-1378.
FULL TEXT  

Treatment of Obesity
Thompson et al.
Mayo Clin Proc. 2007;82:93-102.
ABSTRACT | FULL TEXT  

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher et al.
Pharmacol. Rev. 2006;58:389-462.
ABSTRACT | FULL TEXT  

Simple Pill Not a Simple Answer to Obesity
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT